Combination Therapy of PPARγ Ligands and Inhibitors of Arachidonic Acid in Lung Cancer

Abstract EN

Lung cancer is the leading cause of cancer death in the United States and five-year survival remains low.

Numerous studies have shown that chronic inflammation may lead to progression of carcinogenesis.

As a result of inflammatory stimulation, arachidonic acid (AA) metabolism produces proliferation mediators through complex and dynamic interactions of the products of the LOX/COX enzymes.

One important mediator in the activation of the AA pathways is the nuclear protein PPARγ.

Targeting LOX/COX enzymes and inducing activation of PPARγ have resulted in significant reduction of cell growth in lung cancer cell lines.

However, specific COX-inhibitors have been correlated with an increased cardiovascular risk.

Clinical applications are still being explored with a novel generation of dual LOX/COX inhibitors.

PPARγ activation through synthetic ligands (TZDs) has revealed a great mechanistic complexity since effects are produced through PPARγ-dependent and -independent mechanisms.

Furthermore, PPARγ could also be involved in regulation of COX-2.

Overexpression of PPARγ has reported to play a role in control of invasion and differentiation.

Exploring the function of PPARγ, in this new context, may provide a better mechanistic model of its role in cancer and give an opportunity to design a more efficient therapeutic approach in combination with LOX/COX inhibitors.